Przejdź do treści

Filtry

Dane naukowe

Podręcznik/instrukcje

Aktualności

What are the benefits and harms of different SARS-CoV-2 testing methods when trying to stop people from getting sick, going to the hospital, or dying?

Key messages

  • Few studies examine how severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) tests assist or hinder efforts to prevent illness, hospitalisations, or people dying.

  • Due to weak evidence, we’re uncertain if testing helps prevent people from getting sick.

  • There isn’t enough research to clearly show the benefits or harms of different types of SARS-CoV-2 testing for preventing illness, hospital stays, or deaths.

What is SARS-CoV-2?

A new virus called SARS-CoV-2 was discovered in China in December 2019. By May 2024, it had infected 775 million people with COVID-19, and more than seven million people had died. Testing people for the virus can help healthcare workers identify when more people are becoming ill, allowing them to act quickly to keep others safe.

What did we want to find out?

We looked at how well different SARS-CoV-2 testing methods work to help stop people from getting sick, going to the hospital, or dying. We also wanted to find out if SARS-CoV-2 testing was associated with any unwanted effects.

What did we do?

We looked for studies that compared different SARS-CoV-2 testing strategies for people with and without symptoms, examined what the studies found, and summarised the results. We presented the main comparisons that we decided in advance. We also rated our confidence in the evidence, based on things like how the studies were done and how many people took part.

What did we find?

We found 21 studies, with 13,312,327 people, that examined the benefits and harms of various SARS-CoV-2 tests. However, only four of these studies, with 190,821 people, measured results that we were interested in.

Main results

One study, conducted in a long-term care facility in Israel, measured the effect of weekly SARS-CoV-2 tests on the number of people who were admitted to hospital or who died for the comparison: testing strategy versus no testing or standard care or usual practice. The study did not measure COVID-19 cases avoided, or serious unwanted effects related to testing. No studies measured these results for the comparison: testing strategy versus another testing strategy.

Benefits and harms of testing strategy versus no testing or standard care or usual practice

We are very uncertain about the results on the number of people admitted to hospital and deaths, based on the one included study that looked at the effect of weekly SARS-CoV-2 testing compared to no testing.

What are the limitations of the evidence?

We found a few studies. The evidence we examined from two results—comparing testing to no testing—wasn’t very strong because it was from a single study, the study had problems with how it was done, and it didn’t align well with the question. The results might not be completely fair or accurate because other factors got mixed in, and how results were measured could have been faulty. Further research is likely to change our results.

How up to date is this evidence?

The evidence is up-to-date as of 07 October 2024.

Cele

To evaluate the effectiveness of different SARS-CoV-2 testing strategies in reducing COVID-19 cases, hospitalisations, and deaths amongst suspected cases and asymptomatic individuals.

Metody wyszukiwania badań

We searched CENTRAL, MEDLINE (Ovid), Embase (Elsevier), Europe PMC, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform. We also conducted reference checks, citation searches, and contacted study authors to identify eligible studies. The most recent search was conducted on 07 October 2024.

Wnioski autorów

The available data are of very low-certainty. Only one of the 21 included studies reported hospitalisations or deaths; therefore, we cannot draw conclusions about the effects of testing strategy versus no testing on reducing hospitalisation and mortality. No studies evaluated other critical outcomes i.e. COVID-19 cases avoided, and serious adverse events related to testing. Future research should aim for consistency and relevance by using clearly defined outcomes, preferably based on a standardised core outcome set. A qualitative evidence synthesis (QES) would help identify barriers and facilitators to routine SARS-CoV-2 testing in healthcare settings, which could help inform intervention development. The QES would explore factors affecting the implementation of routine testing, drawing on the perspectives of healthcare providers, patients, and other interest holders.

Finansowanie

This Cochrane review was partially funded by the World Health Organization (WHO) and the Health Research Board of Ireland.

Rejestracja

Protocol (2025) DOI : 10.1002/14651858.CD016192

Cytowanie
Saif-Ur-Rahman K, Nurdin N, Movsisyan A, Kothari K, Gleeson C, Conway T, Tierney M, Taneri PE, Mulholland D, Tricco AC, Dinnes J, Devane D. Effectiveness of SARS-CoV-2 testing strategies in reducing COVID-19 cases, hospitalisations, and deaths. Cochrane Database of Systematic Reviews 2025, Issue 10. Art. No.: CD016192. DOI: 10.1002/14651858.CD016192.pub2.

Używamy plików cookie

Używamy niezbędnych plików cookie, aby nasza strona mogła działać. Chcielibyśmy również ustawić opcjonalne pliki cookie do analizy, aby pomóc nam udoskonalić tę stronę. Nie będziemy ustawiać opcjonalnych plików cookie, chyba że je włączysz. Użycie tego narzędzia spowoduje ustawienie pliku cookie na Twoim urządzeniu, aby zapamiętać Twoje preferencje. W każdej chwili możesz zmienić swoje preferencje dotyczące plików cookie, klikając na link "Ustawienia plików cookie" znajdujący się w stopce każdej strony.
Bardziej szczegółowe informacje na temat używanych przez nas plików cookie można znaleźć na naszej stronieStrona plików cookies

Zaakceptuj wszystkie
Skonfiguruj